Tolvaptan - Otsuka Pharmaceutical
Alternative Names: Jinarc; Jynarque; OPC 61815; OPC-156; OPC-41061; Samsca; Samsca granules 1%; SAMTASU; Samtasu; Tolvaptan sodium phosphate - Otsuka PharmaceuticalLatest Information Update: 24 May 2024
At a glance
- Originator Otsuka America Pharmaceutical; Otsuka Pharmaceutical
- Class Antihypertensives; Benzazepines; Heart failure therapies; Small molecules; Urologics
- Mechanism of Action Diuretics; Vasopressin V2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Autosomal dominant polycystic kidney disease; Cardiac oedema; Hyponatraemia; Oedema
- Registered Ascites; Heart failure; Renal failure
- Phase II Benign prostatic hyperplasia
- No development reported Cystinuria; Unspecified
Most Recent Events
- 24 May 2024 Preregistration for Cardiac oedema in China (IV) (Otsuka Pharmaceutical pipeline; May 2024)
- 21 Sep 2022 Otsuka Beijing Research Institute completes a phase I pharmacokinetics trial in healthy Chinese male volunteers in China (IV) (NCT05439148)
- 15 Jul 2022 Phase-III clinical trials in Autosomal dominant polycystic kidney disease (In adolescents, In children, In infants) in Germany, USA (PO) (Tablet) (NCT04782258)